Hutchmed (China) Limited (HCM) ORD USD0.10
![](https://online.hl.co.uk/img/hl/layout/security-down-arrow.gif)
- Add to watchlist
- Create an alert
- This stock can be held in a
![](https://online.hl.co.uk/img/hl/layout/security-down-arrow.gif)
![Deal now](https://online.hl.co.uk/img/form-buttons/deal-now-button.jpg)
![](https://online.hl.co.uk/img/hl/layout/security-down-arrow.gif)
![Deal now](https://online.hl.co.uk/img/form-buttons/deal-now-button.jpg)
300.00p
300.00p
353.00p
£2.46 bn
304.00p
284.00p
190.40p
32.58
7.00p (2.36%) Previous:
7.00p
65,873
n/a
1,000
Performance
1 week 1W | 7.69% | 1 year 1Y | 31.66% |
---|---|---|---|
1 month 1M | 0.35% | 2 years 2Y | 31.51% |
3 months 3M | 14.54% | 3 years 3Y | 49.74% |
6 months 6M | 24.95% | 5 years 5Y | 12.33% |
Performance figures are based on the previous close price. Past performance is not an indication of future performance.
Fundamental data
Year ending: | 31/12/2023 | 31/12/2022 |
---|---|---|
Revenue ($m) | 838.00 | 426.41 |
Profit before tax ($m) | 58.31 | (410.42) |
Adjusted EPS (¢): | 12.00 | (43.00) |
P/E ratio | 30.50 | n/a |
PEG | n/a | n/a |
EPS growth (%) | n/a | n/a |
Values are quoted in the stock's local currency: US dollar
All fundamental dataDividend information for this stock is not available.
Dividend information for this stock is not available.
Ready to invest?
Important Documents
There are no documents available for this stock.
-
Oncology revenue drives first-half growth for Hutchmed
31 July 2024 12:16
-
Hutchmed gets tazemetostat new drug application approved in China
4 July 2024 14:03
-
Hutchmed partner gets European approval for fruqintinib
24 June 2024 12:20
-
LTIP and Share Option Scheme
6 August 2024 10:00
-
2024 Interim Results and Business Updates
31 July 2024 12:00
![Deal now](https://online.hl.co.uk/img/form-buttons/deal-now-button.jpg)
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.